{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:58:54Z","timestamp":1771865934665,"version":"3.50.1"},"reference-count":60,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec id=\"st1\">\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Flow cytometry is often applied to minimal residual disease (MRD) testing in hematolymphoid neoplasia. Because flow-based MRD tests are developed in the laboratory, testing methodologies and lower levels of detection (LODs) are laboratory dependent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st2\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To broadly survey flow cytometry laboratories about MRD testing in laboratories, if performed, including indications and reported LODs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st3\">\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Voluntary supplemental questions were sent to the 549 laboratories participating in the College of American Pathologists (CAP) FL3-A Survey (Flow Cytometry\u2014Immunophenotypic Characterization of Leukemia\/Lymphoma) in the spring of 2014.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st4\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 500 laboratories (91%) responded to the supplemental questions as part of the FL3-A Survey by April 2014; of those 500 laboratories, 167 (33%) currently perform MRD for lymphoblastic leukemia, 118 (24%) for myeloid leukemia, 99 (20%) for chronic lymphocytic leukemia, and 91 (18%) for plasma cell myeloma. Other indications include non-Hodgkin lymphoma, hairy cell leukemia, neuroblastoma, and myelodysplastic syndrome. Most responding laboratories that perform MRD for lymphoblastic leukemia reported an LOD of 0.01%. For myeloid leukemia, chronic lymphocytic leukemia, and plasma cell myeloma, most laboratories indicated an LOD of 0.1%. Less than 3% (15 of 500) of laboratories reported LODs of 0.001% for one or more MRD assays performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st5\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is major heterogeneity in the reported LODs of MRD testing performed by laboratories subscribing to the CAP FL3-A Survey. To address that heterogeneity, changes to the Flow Cytometry Checklist for the CAP Laboratory Accreditation Program are suggested that will include new requirements that each laboratory (1) document how an MRD assay's LOD is measured, and (2) include the LOD or lower limit of enumeration for flow-based MRD assays in the final diagnostic report.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2014-0543-cp","type":"journal-article","created":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T09:20:15Z","timestamp":1424337615000},"page":"1276-1280","source":"Crossref","is-referenced-by-count":32,"title":["Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program"],"prefix":"10.5858","volume":"139","author":[{"given":"Michael","family":"Keeney","sequence":"first","affiliation":[{"name":"From the Department of Hematology, London Health Sciences Centre, London, Ontario, Canada (Mr Keeney); the Department of Surveys, College of American Pathologists, Northfield, Illinois (Ms Halley); the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Rhoads); the Department of Clinical Pathology, Cleveland Clinic, Cleveland, Ohio (Dr Ansari); PhenoPath, Seattle, Washington (Dr Kussick); the Department of Laboratory Medicine, University of California..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimie G.","family":"Halley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Rhoads","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Qasim","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Kussick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Karlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumudini U.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Dorfman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Linden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"issue":"8","key":"i1543-2165-139-10-1276-b01","series-title":"Blood","first-page":"3941","article-title":"Flow cytometric immunophenotyping for hematologic neoplasms","volume":"111","author":"Craig\n              FE,","year":"2008","unstructured":"Craig\n              FE, \n            \n              Foon\n              KA.\n            \n          \n          Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111(8):3941\u20133967."},{"issue":"4","key":"i1543-2165-139-10-1276-b02","series-title":"Cytometry","first-page":"139","article-title":"Detection of minimal residual disease in acute leukemia by flow cytometry","volume":"38","author":"Campana\n              D,","year":"1999","unstructured":"Campana\n              D, \n            \n              Coustan-Smith\n              E.\n            \n          \n          Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38(4):139\u2013152."},{"issue":"2","key":"i1543-2165-139-10-1276-b03","series-title":"Cytokines Mol Ther","first-page":"121","article-title":"Detection of minimal residual disease in acute leukemia patients","volume":"2","author":"van Dongen\n              JJ,","year":"1996","unstructured":"van Dongen\n              JJ, \n            \n              Szczepa\u0144ski\n              T, \n            \n              de Bruijn\n              MA, \n            et al\n          . Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther. 1996;2(2):121\u2013133."},{"issue":"3","key":"i1543-2165-139-10-1276-b04","series-title":"Curr Hematol Malig Rep","first-page":"169","article-title":"Progress of minimal residual disease studies in childhood acute leukemia","volume":"5","author":"Campana\n              D.","year":"2010","unstructured":"Campana\n              D.\n            \n          \n          Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep. 2010;5(3):169\u2013176."},{"issue":"12","key":"i1543-2165-139-10-1276-b05","series-title":"Blood","first-page":"5477","article-title":"Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study","volume":"111","author":"Borowitz\n              MJ,","year":"2008","unstructured":"Borowitz\n              MJ, \n            \n              Devidas\n              M, \n            \n              Hunger\n              SP, \n            et al;\n          \n          Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477\u20135485."},{"issue":"6","key":"i1543-2165-139-10-1276-b06","series-title":"Blood","first-page":"1952","article-title":"Austrian Berlin-Frankfurt-M\u00fcnster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"99","author":"Dworzak\n              MN,","year":"2002","unstructured":"Dworzak\n              MN, \n            \n              Fr\u00f6schl\n              G, \n            \n              Printz\n              D, \n            et al;\n          \n          Austrian Berlin-Frankfurt-M\u00fcnster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99(6):1952\u20131958."},{"issue":"1","key":"i1543-2165-139-10-1276-b07","series-title":"Br J Haematol","first-page":"241","article-title":"Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome","volume":"105","author":"Griesinger\n              F,","year":"1999","unstructured":"Griesinger\n              F, \n            \n              Pir\u00f2-Noack\n              M, \n            \n              Kaib\n              N, \n            et al\n          . Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. Br J Haematol. 1999;105(1):241\u2013255."},{"issue":"8","key":"i1543-2165-139-10-1276-b08","series-title":"Haematologica","first-page":"1109","article-title":"Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia","volume":"91","author":"Krampera\n              M,","year":"2006","unstructured":"Krampera\n              M, \n            \n              Perbellini\n              O, \n            \n              Vincenzi\n              C, \n            et al\n          . Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica. 2006;91(8):1109\u20131112."},{"issue":"5","key":"i1543-2165-139-10-1276-b09","series-title":"Leukemia","first-page":"934","article-title":"Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"18","author":"Neale\n              GA,","year":"2004","unstructured":"Neale\n              GA, \n            \n              Coustan-Smith\n              E, \n            \n              Stow\n              P, \n            et al\n          . Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2004;18(5):934\u2013938."},{"issue":"6","key":"i1543-2165-139-10-1276-b10","series-title":"Blood","first-page":"1746","article-title":"Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification","volume":"98","author":"San Miguel\n              JF,","year":"2001","unstructured":"San Miguel\n              JF, \n            \n              Vidriales\n              MB, \n            \n              L\u00f3pez-Berges\n              C, \n            et al\n          . Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98(6):1746\u20131751."},{"issue":"9","key":"i1543-2165-139-10-1276-b11","series-title":"Blood","first-page":"3398","article-title":"Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia","volume":"101","author":"Sievers\n              EL,","year":"2003","unstructured":"Sievers\n              EL, \n            \n              Lange\n              BJ, \n            \n              Alonzo\n              TA, \n            et al\n          . Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003;101(9):3398\u20133406."},{"issue":"2","key":"i1543-2165-139-10-1276-b12","series-title":"Crit Rev Oncol Hematol","first-page":"283","article-title":"Monitoring of minimal residual disease in acute myeloid leukemia","volume":"56","author":"Kern\n              W,","year":"2005","unstructured":"Kern\n              W, \n            \n              Schoch\n              C, \n            \n              Haferlach\n              T, \n            \n              Schnittger\n              S.\n            \n          \n          Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol. 2005;56(2):283\u2013309."},{"issue":"10","key":"i1543-2165-139-10-1276-b13","series-title":"Blood","first-page":"1813","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter\n              RB,","year":"2013","unstructured":"Walter\n              RB, \n            \n              Buckley\n              SA, \n            \n              Pagel\n              JM, \n            et al\n          . Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122(10):1813\u20131821."},{"issue":"31","key":"i1543-2165-139-10-1276-b14","series-title":"J Clin Oncol","first-page":"3889","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn\n              M,","year":"2013","unstructured":"Terwijn\n              M, \n            \n              van Putten\n              WL, \n            \n              Kelder\n              A, \n            et al\n          . High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889\u20133897."},{"issue":"1","key":"i1543-2165-139-10-1276-b15","series-title":"Blood","first-page":"29","article-title":"Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy","volume":"98","author":"Rawstron\n              AC,","year":"2001","unstructured":"Rawstron\n              AC, \n            \n              Kennedy\n              B, \n            \n              Evans\n              PA, \n            et al\n          . Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98(1):29\u201335."},{"issue":"10","key":"i1543-2165-139-10-1276-b16","series-title":"Leukemia","first-page":"1637","article-title":"Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation","volume":"18","author":"B\u00f6ttcher\n              S,","year":"2004","unstructured":"B\u00f6ttcher\n              S, \n            \n              Ritgen\n              M, \n            \n              Pott\n              C, \n            et al\n          . Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia. 2004;18(10):1637\u20131645."},{"issue":"11","key":"i1543-2165-139-10-1276-b17","series-title":"Blood","first-page":"4563","article-title":"Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia","volume":"107","author":"Moreno\n              C,","year":"2006","unstructured":"Moreno\n              C, \n            \n              Villamor\n              N, \n            \n              Colomer\n              D, \n            et al\n          . Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006;107(11):4563\u20134569."},{"issue":"5","key":"i1543-2165-139-10-1276-b18","series-title":"Leukemia","first-page":"956","article-title":"International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia","volume":"21","author":"Rawstron\n              AC,","year":"2007","unstructured":"Rawstron\n              AC, \n            \n              Villamor\n              N, \n            \n              Ritgen\n              M, \n            et al\n          . International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21(5):956\u2013964."},{"issue":"9","key":"i1543-2165-139-10-1276-b19","series-title":"J Clin Oncol","first-page":"980","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher\n              S,","year":"2012","unstructured":"B\u00f6ttcher\n              S, \n            \n              Ritgen\n              M, \n            \n              Fischer\n              K, \n            et al\n          . Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980\u2013988."},{"issue":"10","key":"i1543-2165-139-10-1276-b20","series-title":"Blood","first-page":"4017","article-title":"GEM (Grupo Espa\u00f1ol de MM)\/PETHEMA (Programa para el Estudio de la Terap\u00e9utica en Hemopat\u00edas Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva\n              B,","year":"2008","unstructured":"Paiva\n              B, \n            \n              Vidriales\n              MB, \n            \n              Cerver\u00f3\n              J, \n            et al;\n          \n          GEM (Grupo Espa\u00f1ol de MM)\/PETHEMA (Programa para el Estudio de la Terap\u00e9utica en Hemopat\u00edas Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017\u20134023."},{"issue":"12","key":"i1543-2165-139-10-1276-b21","series-title":"J Clin Oncol","first-page":"1627","article-title":"Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma","volume":"29","author":"Paiva\n              B,","year":"2011","unstructured":"Paiva\n              B, \n            \n              Martinez-Lopez\n              J, \n            \n              Vidriales\n              MB, \n            et al\n          . Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011;29(12):1627\u20131633."},{"issue":"12","key":"i1543-2165-139-10-1276-b22","series-title":"Biol Blood Marrow Transplant","first-page":"1790","article-title":"Minimal residual disease in myeloma: are we there yet?","volume":"18","author":"Hart\n              AJ,","year":"2012","unstructured":"Hart\n              AJ, \n            \n              Jagasia\n              MH, \n            \n              Kim\n              AS, \n            \n              Mosse\n              CA, \n            \n              Savani\n              BN, \n            \n              Kassim\n              A.\n            \n          \n          Minimal residual disease in myeloma: are we there yet?\n          Biol Blood Marrow Transplant. 2012;18(12):1790\u20131799."},{"issue":"5","key":"i1543-2165-139-10-1276-b23","series-title":"Am J Clin Pathol","first-page":"728","article-title":"Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma","volume":"132","author":"Gupta\n              R,","year":"2009","unstructured":"Gupta\n              R, \n            \n              Bhaskar\n              A, \n            \n              Kumar\n              L, \n            \n              Sharma\n              A, \n            \n              Jain\n              P.\n            \n          \n          Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Am J Clin Pathol. 2009;132(5):728\u2013732."},{"issue":"16","key":"i1543-2165-139-10-1276-b24","series-title":"J Clin Oncol","first-page":"2737","article-title":"PETHEMA Study Group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM Cooperative Study Groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo\n              G,","year":"2008","unstructured":"Mateo\n              G, \n            \n              Montalb\u00e1n\n              MA, \n            \n              Vidriales\n              MB, \n            et al;\n          \n          PETHEMA Study Group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM Cooperative Study Groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26(16):2737\u20132744."},{"issue":"5","key":"i1543-2165-139-10-1276-b25","series-title":"J Mol Diagn","first-page":"556","article-title":"Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation","volume":"15","author":"Zhen\n              C,","year":"2013","unstructured":"Zhen\n              C, \n            \n              Wang\n              YL.\n            \n          \n          Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation. J Mol Diagn. 2013;15(5):556\u2013564."},{"issue":"5","key":"i1543-2165-139-10-1276-b26","series-title":"Leukemia","first-page":"1131","article-title":"What does MRD in leukemia really mean?","volume":"28","author":"Goldman\n              JM,","year":"2014","unstructured":"Goldman\n              JM, \n            \n              Gale\n              RP.\n            \n          \n          What does MRD in leukemia really mean?\n          Leukemia. 2014;28(5):1131."},{"issue":"6","key":"i1543-2165-139-10-1276-b27","series-title":"Blood","first-page":"1088","article-title":"Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity","volume":"122","author":"Flanders\n              A,","year":"2013","unstructured":"Flanders\n              A, \n            \n              Stetler-Stevenson\n              M, \n            \n              Landgren\n              O.\n            \n          \n          Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood. 2013;122(6):1088\u20131089."},{"issue":"5","key":"i1543-2165-139-10-1276-b28","series-title":"Cytometry B Clin Cytom","first-page":"315","article-title":"ICSH\/ICCS Working Group. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS, part V: assay performance criteria","volume":"84","author":"Wood\n              B,","year":"2013","unstructured":"Wood\n              B, \n            \n              Jevremovic\n              D, \n            \n              B\u00e9n\u00e9\n              MC, \n            et al;\n          \n          ICSH\/ICCS Working Group. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS, part V: assay performance criteria. Cytometry B Clin Cytom. 2013;84(5):315\u2013323."},{"issue":"3","key":"i1543-2165-139-10-1276-b29","series-title":"Int J Lab Hematol","first-page":"344","article-title":"Technical issues: flow cytometry and rare event analysis","volume":"35","author":"Hedley\n              BD,","year":"2013","unstructured":"Hedley\n              BD, \n            \n              Keeney\n              M.\n            \n          \n          Technical issues: flow cytometry and rare event analysis. Int J Lab Hematol. 2013;35(3):344\u2013350."},{"issue":"6","key":"i1543-2165-139-10-1276-b30","series-title":"Pediatr Blood Cancer","first-page":"957","article-title":"COG Acute Lymphoblastic Leukemia Committee. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia","volume":"60","author":"Hunger\n              SP,","year":"2013","unstructured":"Hunger\n              SP, \n            \n              Loh\n              ML, \n            \n              Whitlock\n              JA, \n            et al;\n          \n          COG Acute Lymphoblastic Leukemia Committee. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(6):957\u2013963."},{"issue":"8","key":"i1543-2165-139-10-1276-b01","series-title":"Blood","first-page":"3941","article-title":"Flow cytometric immunophenotyping for hematologic neoplasms","volume":"111","author":"Craig\n              FE,","year":"2008","unstructured":"Craig\n              FE, \n            \n              Foon\n              KA.\n            \n          \n          Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111(8):3941\u20133967."},{"issue":"4","key":"i1543-2165-139-10-1276-b02","series-title":"Cytometry","first-page":"139","article-title":"Detection of minimal residual disease in acute leukemia by flow cytometry","volume":"38","author":"Campana\n              D,","year":"1999","unstructured":"Campana\n              D, \n            \n              Coustan-Smith\n              E.\n            \n          \n          Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38(4):139\u2013152."},{"issue":"2","key":"i1543-2165-139-10-1276-b03","series-title":"Cytokines Mol Ther","first-page":"121","article-title":"Detection of minimal residual disease in acute leukemia patients","volume":"2","author":"van Dongen\n              JJ,","year":"1996","unstructured":"van Dongen\n              JJ, \n            \n              Szczepa\u0144ski\n              T, \n            \n              de Bruijn\n              MA, \n            et al\n          . Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther. 1996;2(2):121\u2013133."},{"issue":"3","key":"i1543-2165-139-10-1276-b04","series-title":"Curr Hematol Malig Rep","first-page":"169","article-title":"Progress of minimal residual disease studies in childhood acute leukemia","volume":"5","author":"Campana\n              D.","year":"2010","unstructured":"Campana\n              D.\n            \n          \n          Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep. 2010;5(3):169\u2013176."},{"issue":"12","key":"i1543-2165-139-10-1276-b05","series-title":"Blood","first-page":"5477","article-title":"Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study","volume":"111","author":"Borowitz\n              MJ,","year":"2008","unstructured":"Borowitz\n              MJ, \n            \n              Devidas\n              M, \n            \n              Hunger\n              SP, \n            et al;\n          \n          Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477\u20135485."},{"issue":"6","key":"i1543-2165-139-10-1276-b06","series-title":"Blood","first-page":"1952","article-title":"Austrian Berlin-Frankfurt-M\u00fcnster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"99","author":"Dworzak\n              MN,","year":"2002","unstructured":"Dworzak\n              MN, \n            \n              Fr\u00f6schl\n              G, \n            \n              Printz\n              D, \n            et al;\n          \n          Austrian Berlin-Frankfurt-M\u00fcnster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99(6):1952\u20131958."},{"issue":"1","key":"i1543-2165-139-10-1276-b07","series-title":"Br J Haematol","first-page":"241","article-title":"Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome","volume":"105","author":"Griesinger\n              F,","year":"1999","unstructured":"Griesinger\n              F, \n            \n              Pir\u00f2-Noack\n              M, \n            \n              Kaib\n              N, \n            et al\n          . Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. Br J Haematol. 1999;105(1):241\u2013255."},{"issue":"8","key":"i1543-2165-139-10-1276-b08","series-title":"Haematologica","first-page":"1109","article-title":"Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia","volume":"91","author":"Krampera\n              M,","year":"2006","unstructured":"Krampera\n              M, \n            \n              Perbellini\n              O, \n            \n              Vincenzi\n              C, \n            et al\n          . Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica. 2006;91(8):1109\u20131112."},{"issue":"5","key":"i1543-2165-139-10-1276-b09","series-title":"Leukemia","first-page":"934","article-title":"Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"18","author":"Neale\n              GA,","year":"2004","unstructured":"Neale\n              GA, \n            \n              Coustan-Smith\n              E, \n            \n              Stow\n              P, \n            et al\n          . Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2004;18(5):934\u2013938."},{"issue":"6","key":"i1543-2165-139-10-1276-b10","series-title":"Blood","first-page":"1746","article-title":"Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification","volume":"98","author":"San Miguel\n              JF,","year":"2001","unstructured":"San Miguel\n              JF, \n            \n              Vidriales\n              MB, \n            \n              L\u00f3pez-Berges\n              C, \n            et al\n          . Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98(6):1746\u20131751."},{"issue":"9","key":"i1543-2165-139-10-1276-b11","series-title":"Blood","first-page":"3398","article-title":"Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia","volume":"101","author":"Sievers\n              EL,","year":"2003","unstructured":"Sievers\n              EL, \n            \n              Lange\n              BJ, \n            \n              Alonzo\n              TA, \n            et al\n          . Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003;101(9):3398\u20133406."},{"issue":"2","key":"i1543-2165-139-10-1276-b12","series-title":"Crit Rev Oncol Hematol","first-page":"283","article-title":"Monitoring of minimal residual disease in acute myeloid leukemia","volume":"56","author":"Kern\n              W,","year":"2005","unstructured":"Kern\n              W, \n            \n              Schoch\n              C, \n            \n              Haferlach\n              T, \n            \n              Schnittger\n              S.\n            \n          \n          Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol. 2005;56(2):283\u2013309."},{"issue":"10","key":"i1543-2165-139-10-1276-b13","series-title":"Blood","first-page":"1813","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter\n              RB,","year":"2013","unstructured":"Walter\n              RB, \n            \n              Buckley\n              SA, \n            \n              Pagel\n              JM, \n            et al\n          . Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122(10):1813\u20131821."},{"issue":"31","key":"i1543-2165-139-10-1276-b14","series-title":"J Clin Oncol","first-page":"3889","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn\n              M,","year":"2013","unstructured":"Terwijn\n              M, \n            \n              van Putten\n              WL, \n            \n              Kelder\n              A, \n            et al\n          . High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J Clin Oncol. 2013;31(31):3889\u20133897."},{"issue":"1","key":"i1543-2165-139-10-1276-b15","series-title":"Blood","first-page":"29","article-title":"Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy","volume":"98","author":"Rawstron\n              AC,","year":"2001","unstructured":"Rawstron\n              AC, \n            \n              Kennedy\n              B, \n            \n              Evans\n              PA, \n            et al\n          . Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98(1):29\u201335."},{"issue":"10","key":"i1543-2165-139-10-1276-b16","series-title":"Leukemia","first-page":"1637","article-title":"Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation","volume":"18","author":"B\u00f6ttcher\n              S,","year":"2004","unstructured":"B\u00f6ttcher\n              S, \n            \n              Ritgen\n              M, \n            \n              Pott\n              C, \n            et al\n          . Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia. 2004;18(10):1637\u20131645."},{"issue":"11","key":"i1543-2165-139-10-1276-b17","series-title":"Blood","first-page":"4563","article-title":"Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia","volume":"107","author":"Moreno\n              C,","year":"2006","unstructured":"Moreno\n              C, \n            \n              Villamor\n              N, \n            \n              Colomer\n              D, \n            et al\n          . Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006;107(11):4563\u20134569."},{"issue":"5","key":"i1543-2165-139-10-1276-b18","series-title":"Leukemia","first-page":"956","article-title":"International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia","volume":"21","author":"Rawstron\n              AC,","year":"2007","unstructured":"Rawstron\n              AC, \n            \n              Villamor\n              N, \n            \n              Ritgen\n              M, \n            et al\n          . International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21(5):956\u2013964."},{"issue":"9","key":"i1543-2165-139-10-1276-b19","series-title":"J Clin Oncol","first-page":"980","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher\n              S,","year":"2012","unstructured":"B\u00f6ttcher\n              S, \n            \n              Ritgen\n              M, \n            \n              Fischer\n              K, \n            et al\n          . Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980\u2013988."},{"issue":"10","key":"i1543-2165-139-10-1276-b20","series-title":"Blood","first-page":"4017","article-title":"GEM (Grupo Espa\u00f1ol de MM)\/PETHEMA (Programa para el Estudio de la Terap\u00e9utica en Hemopat\u00edas Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva\n              B,","year":"2008","unstructured":"Paiva\n              B, \n            \n              Vidriales\n              MB, \n            \n              Cerver\u00f3\n              J, \n            et al;\n          \n          GEM (Grupo Espa\u00f1ol de MM)\/PETHEMA (Programa para el Estudio de la Terap\u00e9utica en Hemopat\u00edas Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017\u20134023."},{"issue":"12","key":"i1543-2165-139-10-1276-b21","series-title":"J Clin Oncol","first-page":"1627","article-title":"Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma","volume":"29","author":"Paiva\n              B,","year":"2011","unstructured":"Paiva\n              B, \n            \n              Martinez-Lopez\n              J, \n            \n              Vidriales\n              MB, \n            et al\n          . Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011;29(12):1627\u20131633."},{"issue":"12","key":"i1543-2165-139-10-1276-b22","series-title":"Biol Blood Marrow Transplant","first-page":"1790","article-title":"Minimal residual disease in myeloma: are we there yet?","volume":"18","author":"Hart\n              AJ,","year":"2012","unstructured":"Hart\n              AJ, \n            \n              Jagasia\n              MH, \n            \n              Kim\n              AS, \n            \n              Mosse\n              CA, \n            \n              Savani\n              BN, \n            \n              Kassim\n              A.\n            \n          \n          Minimal residual disease in myeloma: are we there yet?\n          Biol Blood Marrow Transplant. 2012;18(12):1790\u20131799."},{"issue":"5","key":"i1543-2165-139-10-1276-b23","series-title":"Am J Clin Pathol","first-page":"728","article-title":"Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma","volume":"132","author":"Gupta\n              R,","year":"2009","unstructured":"Gupta\n              R, \n            \n              Bhaskar\n              A, \n            \n              Kumar\n              L, \n            \n              Sharma\n              A, \n            \n              Jain\n              P.\n            \n          \n          Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Am J Clin Pathol. 2009;132(5):728\u2013732."},{"issue":"16","key":"i1543-2165-139-10-1276-b24","series-title":"J Clin Oncol","first-page":"2737","article-title":"PETHEMA Study Group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM Cooperative Study Groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo\n              G,","year":"2008","unstructured":"Mateo\n              G, \n            \n              Montalb\u00e1n\n              MA, \n            \n              Vidriales\n              MB, \n            et al;\n          \n          PETHEMA Study Group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM Cooperative Study Groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26(16):2737\u20132744."},{"issue":"5","key":"i1543-2165-139-10-1276-b25","series-title":"J Mol Diagn","first-page":"556","article-title":"Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation","volume":"15","author":"Zhen\n              C,","year":"2013","unstructured":"Zhen\n              C, \n            \n              Wang\n              YL.\n            \n          \n          Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation. J Mol Diagn. 2013;15(5):556\u2013564."},{"issue":"5","key":"i1543-2165-139-10-1276-b26","series-title":"Leukemia","first-page":"1131","article-title":"What does MRD in leukemia really mean?","volume":"28","author":"Goldman\n              JM,","year":"2014","unstructured":"Goldman\n              JM, \n            \n              Gale\n              RP.\n            \n          \n          What does MRD in leukemia really mean?\n          Leukemia. 2014;28(5):1131."},{"issue":"6","key":"i1543-2165-139-10-1276-b27","series-title":"Blood","first-page":"1088","article-title":"Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity","volume":"122","author":"Flanders\n              A,","year":"2013","unstructured":"Flanders\n              A, \n            \n              Stetler-Stevenson\n              M, \n            \n              Landgren\n              O.\n            \n          \n          Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood. 2013;122(6):1088\u20131089."},{"issue":"5","key":"i1543-2165-139-10-1276-b28","series-title":"Cytometry B Clin Cytom","first-page":"315","article-title":"ICSH\/ICCS Working Group. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS, part V: assay performance criteria","volume":"84","author":"Wood\n              B,","year":"2013","unstructured":"Wood\n              B, \n            \n              Jevremovic\n              D, \n            \n              B\u00e9n\u00e9\n              MC, \n            et al;\n          \n          ICSH\/ICCS Working Group. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS, part V: assay performance criteria. Cytometry B Clin Cytom. 2013;84(5):315\u2013323."},{"issue":"3","key":"i1543-2165-139-10-1276-b29","series-title":"Int J Lab Hematol","first-page":"344","article-title":"Technical issues: flow cytometry and rare event analysis","volume":"35","author":"Hedley\n              BD,","year":"2013","unstructured":"Hedley\n              BD, \n            \n              Keeney\n              M.\n            \n          \n          Technical issues: flow cytometry and rare event analysis. Int J Lab Hematol. 2013;35(3):344\u2013350."},{"issue":"6","key":"i1543-2165-139-10-1276-b30","series-title":"Pediatr Blood Cancer","first-page":"957","article-title":"COG Acute Lymphoblastic Leukemia Committee. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia","volume":"60","author":"Hunger\n              SP,","year":"2013","unstructured":"Hunger\n              SP, \n            \n              Loh\n              ML, \n            \n              Whitlock\n              JA, \n            et al;\n          \n          COG Acute Lymphoblastic Leukemia Committee. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(6):957\u2013963."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/139\/10\/article-p1276.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/10\/1276\/2275283\/arpa_2014-0543-cp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/139\/10\/article-p1276.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/139\/10\/article-p1276.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:03:56Z","timestamp":1770771836000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/139\/10\/article-p1276.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":60,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2014-0543-cp","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}